Skip to main content

Peri-operative and Post-operative Management of Hemophiliac Patients without Inhibitors

  • Chapter
Orthopedic Surgery in Patients with Hemophilia

Abstract

Orthopedic surgery in patients with hemophilia should be planned by the surgeon together with the hemophilia specialist and the physiotherapist, in order to establish a long-term program that integrates surgery with medical and rehabilitative interventions. Orthopedic surgery should be performed in centres that are able to provide hematologic expertise, medical support, and laboratory monitoring of coagulation throughout the period of hospitalization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-D-Arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet i:869–872

    Article  Google Scholar 

  2. Santagostino E, Mannucci PM (2000) Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 6:1–10

    Article  PubMed  CAS  Google Scholar 

  3. United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) (2003) Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9:1–23

    Article  Google Scholar 

  4. Fletcher ML, Trowell JM, Craske J et al (1983) Non-A, non-B hepatitis after transfusion of factor VIII in unfrequently treated patients. Br Med J 287:1754–1757

    Article  CAS  Google Scholar 

  5. Kernoff PBA, Lee CA, Karayanis P, Thomas HC (1985) High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 60:469–479

    Article  PubMed  CAS  Google Scholar 

  6. Powell DL, Whitener CJ, Dye CE et al (2005) Knee and hip arthroplasty infection rates in persons with haemophilia: a 27 year single center experience during the HIV epidemic. Haemophilia 11:233–239

    Article  PubMed  CAS  Google Scholar 

  7. Wilde JT, Lee CA, Collins P et al (1999) Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 107: 556–569

    Article  PubMed  CAS  Google Scholar 

  8. Martinowitz U, Schulman S, Gitel S et al (1992) Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 82:729–734

    Article  PubMed  CAS  Google Scholar 

  9. Schulman S, Gitel S, Martinowitz U (1994) Stability of factor VIII concentrates after reconstitution. Am J Hematol 45:217–223

    Article  PubMed  CAS  Google Scholar 

  10. Schulman S, Varon D, Keller N et al (1994) Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 72:403–407

    PubMed  CAS  Google Scholar 

  11. Chowdary P, Dasani H, Jones JA et al (2001) Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 7:140–145

    Article  PubMed  CAS  Google Scholar 

  12. Sharathkumar A, Lillicrap D, Blanchette VS et al (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 1:1228–1236

    Article  PubMed  CAS  Google Scholar 

  13. White B, Cotter M, Byrne M et al (2000) High responding factor VIII inhibitors in mild haemophilia — is there a link with recent changes in clinical practice? Haemophilia 6:113–115

    Article  PubMed  CAS  Google Scholar 

  14. Rickard KA (1995) Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1(Suppl 1):8–13

    Article  Google Scholar 

  15. Dingli D, Gastineau DA, Gilchrist GS et al (2002) Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 8:629–634

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Mancuso, M.E., Santagostino, E. (2008). Peri-operative and Post-operative Management of Hemophiliac Patients without Inhibitors. In: Caviglia, H.A., Solimeno, L.P. (eds) Orthopedic Surgery in Patients with Hemophilia. Springer, Milano. https://doi.org/10.1007/978-88-470-0854-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0854-0_6

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0853-3

  • Online ISBN: 978-88-470-0854-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics